Torrent Pharma Ltd

Stock Opportunities Not-so-Hidden Gems
214

FY 16 is a year where torrent has got a windfall gain from abilify. that opportunity will be diluted to a large extent for fy 17. So one needs to guess what torrent’s revenues and profits would be for fy 17 and take a call on valuations.

Till now its a black box and I dont think people will have much idea till q1 fy 17 results will be out. At most domestic business projections can be made with some accuracy while the US biz would be difficult to predict.

Having said that I remain bullish on the company’s prospects having invested in it since before q1 fy 16 results.

9 Likes
215

every pharma company investor must watch . we all part of this.
https://www.youtube.com/watch?v=ASBeOZlujSw

2 Likes
216

Those who know industrial climate in India, are aware that this is true to all industries in India not pharma specific. The environmental agencies are weak and corrupt and hence issues are there. The environmental norms needs to be tightened and this is not a problem which can’t be taken care.
Btw…many times such news are exaggerated and planted by lobbies who are threatened by the competition. So read such articles/news with a pinch of salt.

217

Torrent Pharma : Consolidated Highlights

Consolidated net sales for the year ended March 2015 increased by 13.6 per cent to Rs.4,585 crore from Rs.4,036 crore in the previous year.

Net profit by 13.1 per cent to Rs.751 crore from Rs.664 crore.
Domestic sales went up by 28.7 per cent to Rs.1,882 crore from Rs.1,462 crore and contributed 41 per cent of its total net sales.

International sales moved up by 5 per cent to Rs.2,711 crore from Rs.2,581 crore and contributed 59 per cent to its net sales.

For the nine months ended December 2015
Reserves & surplus Rs.2,406 crore.
Net sales up by 46.5 per cent to Rs.5,056 crore from Rs.3,451 crore in the corresponding period of last year
Net profit went up by 142 per cent to Rs.1,500 crore from Rs.621 crore
Domestic sales increased by 20 per cent to Rs.1,701 crore from Rs.1,418 crore
International sales moved up by 65 per cent to Rs.3,366 crore from Rs.2,039 crore.
EPS for the nine months worked out to Rs.88.62 as compared to Rs.36.67 in the last period.

Sales in US increased to 7.2 per cent to Rs.832 crore from Rs.776 crore in the previous year. The lower growth in US is due to higher revenues from one of the new launches in previous year. Adjusting for oneoffs, revenue grew by 54 per cent. Its sales in Germany increased by 8 per cent to Rs.620 crore. Dossier out licensing and product supply business continues to be an important part of the Europe business and its revenues reached at Rs.221 crore. Its sales in Brazil increased by 14 per cent to Rs.606 crore and it has approvals of 40 products and 20 products are in pending for approvals.

The income from contract manufacturing segment declined to Rs.295 crore during 2014-15 from Rs.393 crore in the previous year, a major portion of which is from manufacture of human insulin.

Focus mainly on CNS, cardiology, diabetes, gastrointestinal and dermatology.The company entered the nephrology market through a new division. It entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in India viz., Rituximab, Adalimumab and Cetuximab.

The company has set up a manufacturing facility for Oyster Shell powder (natural calcium source), a API for manufacture of Shelcal brand. Further it is setting up an integrated manufacturing facility for drug substances and drug products (API and formulations) in oncology for international market. Torrent is also investing in expansion of its Sikkim facility.

Disc : Invested

2 Likes
218

Torrent Pharmaceuticals: A company on fast track

Torrent Pharmaceuticals, a Rs.4,650 crore Ahmedabad based pharma giant, is moving ahead vigorously with expansion and higher investments in R&D. The company is focusing on highly regulated markets and has invested Rs.650 crore in new facility at Dahej in Gujarat. The first phase of new facility was commissioned during November 2015 for the manufacturing of formulations and APIs.

The company added installed capacity of 7,500 million tablets/capsules and 25 MT APIs per annum This plant will export products to highly regulated markets like US, Brazil, Germany, etc. The construction of phase II will commence soon and once commissioned, the total capacity will increase to about 14,000 million tablets/capsules and 80 MT API per year. With the help of 600 scientists, Torrent is well set to established its presence in highly regulated markets in the next couple of years.

Currently, Torrent Pharma’s Rs.5 share is moving in the range of Rs.1,300-1,325 on BSE with market capitalisation of over Rs.22,000 crore. Torrent scrip touched to its yearly high level at Rs.1,720 during September 2015 as against its lowest of Rs.1,033 during February 2015. The promoters are holding 71.25 per cent and remaining is with the public including banks, mutual funds, financial institutions, etc. The company declared hefty interim dividend of Rs.20 per share for a share of Rs.5 each (400 per cent) recently.

The impressive growth in top line and bottom line during the nine months ended December 2015 and an announcement of hefty interim dividend have given necessary push to share price despite depressed investors mood in the stock markets. As against the equity capital of Rs.84.62 crore, its reserves & surplus amounted to Rs.2,406 crore.

For the nine months ended December 2015, Torrent Pharma’s consolidated net sales increased by 46.5 per cent to Rs.5,056 crore from Rs.3,451 crore in the corresponding period of last year. Its net profit went up sharply by 142 per cent to Rs.1,500 crore from Rs.621 crore. Its domestic sales increased by 20 per cent to Rs.1,701 crore from Rs.1,418 crore and international sales moved up by 65 per cent to Rs.3,366 crore from Rs.2,039 crore. EPS for the nine months worked out to Rs.88.62 as compared to Rs.36.67 in the last period.

The company has set up a manufacturing facility for Oyster Shell powder (natural calcium source), a API for manufacture of Shelcal brand. Further it is setting up an integrated manufacturing facility for drug substances and drug products (API and formulations) in oncology for international market. Torrent is also investing in expansion of its Sikkim facility.

Torrent is focusing mainly on CNS, cardiology, diabetes, gastrointestinal and dermatology. With integration of acquired Elder Pharma’s domestic formulation business has assisted well. It is expanding the portfolio in newly entered segments and accelerating performance in the acute segment. The company entered the nephrology market through a new division. It entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in India viz., Rituximab, Adalimumab and Cetuximab.

The company’s consolidated net sales for the year ended March 2015 increased by 13.6 per cent to Rs.4,585 crore from Rs.4,036 crore in the previous year and net profit by 13.1 per cent to Rs.751 crore from Rs.664 crore. Domestic sales went up by 28.7 per cent to Rs.1,882 crore from Rs.1,462 crore and contributed 41 per cent of its total net sales. Its international sales moved up by 5 per cent to Rs.2,711 crore from Rs.2,581 crore and contributed 59 per cent to its net sales. The income from contract manufacturing segment declined to Rs.295 crore during 2014-15 from Rs.393 crore in the previous year, a major portion of which is from manufacture of human insulin.

The company’s sales in US increased to 7.2 per cent to Rs.832 crore from Rs.776 crore in the previous year. The lower growth in US is due to higher revenues from one of the new launches in previous year. Adjusting for oneoffs, revenue grew by 54 per cent. Its sales in Germany increased by 8 per cent to Rs.620 crore. Dossier out licensing and product supply business continues to be an important part of the Europe business and its revenues reached at Rs.221 crore. Its sales in Brazil increased by 14 per cent to Rs.606 crore and it has approvals of 40 products and 20 products are in pending for approvals.

Its R&D expenditure worked out to 4.8 per cent of turnover at Rs.163.57 crore during 2014-15 as against Rs.137.46 crore in the previous year. The company has initiated investment in the areas like oncology, dermatology and opthalmic. It is now planning to spend 6-8 per cent of sales on R&D activities. It received 6 ANDA approval from US FDA and it filed 73 ANDAs and 26 DMFs in the US. It also filed 56 new product dossiers and 24 DMF in the EU. Torrent filed 818 patents for NDDS technology, drug discovery projects and innovative process of API & formulation for various regions and it has been granted 325 patents. The company has initiated new discovery programmes in chronic obstructive pulmonary disease and inflammatory bowel disease.

The company has 17 subsidiaries as at the end of March 2015. It has completed acquisition of domestic branded formulation business of Elder Pharmaceuticals in India and Nepal for a consideration of Rs.2,004 crore during 2014-15 and strengthened its position in women health, pain management, wound care and neutraceuticals therapeutic segments. Further, it entered agreement to acquired 100 per cent stake in Zyg Pharma Pvt Ltd, which engaged in manufacturing various dermatological formulations like creams, ointments, gels, lotions and solutions.

Due to these acquisitions, its fixed assets increased by 148 per cent during 2014-15 to Rs.3,495 crore from Rs.1,409 crore in the previous year. Total borrowings moved up by 162 per cent to Rs.2,504 crore from Rs.954 crore. Its interest burden jumped up by 196 per cent to Rs.175 crore from Rs.59 crore and its depreciation provision increased by 120 per cent to Rs.191 crore from Rs.87 crore.

Based on the first nine months of financial performance and commissioning of new project, Torrent is set to achieve top line growth of 40-45 per cent for the year 2015-16 and net profit growth of around 150 per cent to Rs.2,000 crore, which is far better than the Indian pharma segment. This is better opportunity for investors to increase their investments in Torrent at market price level of around Rs.1,350 on BSE.

http://www.pharmabiz.com/NewsDetails.aspx?aid=93670&sid=1

Disc : Invested

2 Likes
219

Board to consider second interim dividend on 9th March.
Expectation of Rs. 8 dividend

220

I dont understand why they need to declare a second interim dividend in the middle of nowhere. The right time was to declare it when some weeks back they declared interim dividend along with q3 results. Or else it could have been announced with q4 results. Dividends are always welcome though :relaxed:

4 Likes
221

Hiteshji,
This might be due to budget

http://economictimes.indiatimes.com/news/economy/finance/budget-2016-with-10-tax-on-dividend-income-rush-of-interim-payouts-likely/articleshow/51217301.cms

12 Likes
222

I have been patiently waiting to enter Torrent Pharma to make it a significant chunk of my portfolio. Though it is already corrected & could be considered at attractive valuation but I am planning to wait for some more months. Meanwhile I recently found that someone named : DINESHCHANDRA NANCHAND MODI has picked up 1.13% of shares in public domain in the last quarter. I tried to google this name but did not find any clues.

Does anyone know this person?

223

I think lot of companies have announced interim dividend recently instead of final dividend. This is primarily to do with the 10% DDT applicable from April 1 on recipients of more than 10 lakh of dividends. Makes sense also since anyway a company like Torrent which has a stated dividend policy of 30% of PAT will pay dividend after Q4 results are announced. The promoters who hold 75% in the company will save on the tax.

4 Likes
224

Dr Vijay Malik has written a detailed analysis on Torrent Pharma. Check it out here…

225

Torrent Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 09, 2016,
has approved the payment of a special dividend as second interim dividend of Rs.15 (300%) per equity share of Rs. 5/- each fully paid up.

Higher than expected dividend from Torrent.

226

Not sure if it’s the optimum use of Free cash flow. Shouldn’t they use the excess cash to reduce the debt. Besides it also gives the wrong signal of company not able to find opportunities to deploy capital in near term.

2 Likes
227

It is done to avoid taxation. Promoters will not have to pay tax on their dividend income (which will be substantial amount).

228

I am also of the same camp that this is not prudent.

However, one point to note is that management has a stated dividend policy of 30% payout. Back calculation from full year 35rs dividend suggests FY16 EPS of Rs 117. The 9 month EPS was Rs 88 and I would be (pleasantly) surprised if Q4 EPS comes to 117-88=29. Q3 EPS was 28.5 and I was expecting it to drop in Q4.

1 Like
229

Its debtor days value is 105. So may be last Q3 sales still contributing? I am new to investing. Just started an year back. So my perspective may not be correct.

Disc: Invested in TP. It is 10% of my PF.

230

Promoted doesn’t mind the minorities paying thr Hugh interest as long as they get their dividends without income tax. Clearly shows what they care about. Would be doubly wary of the high related party receivables Dr. Mallik pointed out…

231

You should consider that they are running the business in a good and transparent manner. They have had a stated policy of 30% payout and this dividend too has been around that range. Obviously they are the biggest beneficiaries because they hold >70% in the company. I would have also liked to see as much reduction in debt as possible. (In, fact the debt is already reduced sharply). But your statement paints the management as frauds. This is uncalled for.

Regarding receivable days, we need to look at management comments in concall. This increase maybe due to some valid reasons.

232

Bringing the money into the country might have Tax consequences. Would we the shareholders prefer they bring the money into India and pay 30% tax, or hold the money abroad?

Btw, please have a look at this :

Disc: Invested in Torrent, so assume a biased view. Very biased :expressionless:

233

I did not say they are frauds. And I can’t understand how that was
construed. My limited point was promoters have priorities and an important
way for minority shareholders like us to judge them are through such
capital allocation decisions. Nothing more or less.